06/05/2021PRESS RELEASE - Notice of Q1 Results
Philogen S.p.A. will announce its maiden First Quarter 2021 Results on Wednesday 12th May 2021
A virtual briefing will be hosted for sell-side analysts at 10:00am EST / 14:00pm BST / 15:00pm CEST on Thursday 13th May 2021
13/04/2021PRESS RELEASE - PNAS
Philogen announces publication of best-in-class FAP-targeting small molecule ligand (OncoFAP) in PNAS
Study shows impressive tumor uptake of OncoFAP with unprecedented selectivity against healthy organs
OncoFAP-based molecules are currently being developed for the imaging and therapy of cancer
Philogen announces publication of the construction and application of an innovative DNA- encoded chemical library in Nature Chemistry
Study shows the generation of a high-quality stereo- and regiodefined DNA-encoded chemical library.
Identified ligands against tumor-associated antigens can serve as vehicles for pharmacodelivery applications.
PRESS RELEASE - NATURE CHEMISTRY
Philogen will be attending the digital World ADC Europe Conference from March 8 to 11, 2021.
Dr. Samuele Cazzamalli - Head of Small Molecule Therapeutics - will give a Plenary Lecture on: “Small Molecule-Drug Conjugates: Getting Small to Enhance Targeting”.
Philochem announces a publication entitled: “Immunotherapy with immunocytokines and PD-1 blockade enhances the anticancer activity of Small Molecule-Drug Conjugates targeting Carbonic Anhydrase IX”
Link to Paper
Philochem is happy to announce the start of an Innosuissecollaboration with ETH Zurich for the development of Macrocyclic DualPharmacophore DNA-Encoded Chemical Libraries.
The partners will synthesize andvalidate macrocycle-based libraries comprising more than one billion compounds.
These libraries will have a great potential for the identification of ligandsagainst target proteins of biomedical interest with antibody-like properties